Key facts
- This page summarizes Richard William Scalzo's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Dec 2024, 16:05.
Richard William Scalzo - 04 Dec 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)
- Reporting relationship
- SVP, Head of Finance & Admin.
- Issuer ticker
- DYN
- Reported as of
- 04 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Dec 2024, 16:05:14 UTC
- Prior SEC filing
- 18 Nov 2024
- Next SEC filing
- 11 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Scalzo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard William Scalzo filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 06 Dec 2024.
Change
- Previous filing in this sequence was filed on 18 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DYN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +32,700
- Change %
- +34%
- Price
- $0.000000
- Shares after
- 128,533
- Date
- 04 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DYN
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +52,300
- Change %
- Price
- $0.000000
- Shares after
- 52,300
- Date
- 04 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,300
- Exercise price
- $29.44
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of shares of Common Stock issuable under 32,700 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025.
Footnote F2
Includes 122,669 unvested RSUs.
Footnote F3
This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028.